What Researchers Did
Researchers conducted a review of studies published between 1980 and September 2019 to evaluate the therapeutic mechanisms, effects, and efficacy of hyperbaric oxygen therapy (HBOT) in Parkinson's disease and fibromyalgia.
What They Found
Hyperbaric oxygen therapy (HBOT) demonstrated a neuroprotective role in Parkinson's disease models by reducing oxidative stress and neurodegeneration. It was found to improve symptoms and quality of life in fibromyalgia patients, correcting abnormal brain activity in pain-related areas. Evidence from animal studies also supported HBOT's use for other rheumatic diseases by alleviating pain and reducing inflammation.
What This Means for Canadian Patients
While promising, hyperbaric oxygen therapy (HBOT) is not yet a standard treatment for Parkinson's disease or fibromyalgia. Canadian patients should discuss potential alternative therapies with their healthcare providers, but further human research is needed to confirm these benefits.
Canadian Relevance
This review article has no direct Canadian connection as it was not conducted by Canadian researchers, nor did it involve Canadian patients or institutions.
Study Limitations
The primary limitation is that much of the supporting data for hyperbaric oxygen therapy's efficacy comes from animal studies, necessitating further human research to confirm its therapeutic role.